comparemela.com

Latest Breaking News On - Paris based sanofi - Page 3 : comparemela.com

Sanofi makes another mRNA move with deal for skin microbiome biotech Origimm

Sanofi’s strategy to develop new messenger RNA vaccines is adding another piece. The pharmaceutical giant struck a deal to acquire Origimm Biotechnology, a startup developing therapeutic vaccines to treat skin diseases and infections.

Sanofi sees double-digit growth driven by megabrand Dupixent

Sanofi sees double-digit growth driven by megabrand Dupixent
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Sanofi sees double-digit growth driven by megabrand Dupixent

Sanofi sees double-digit growth driven by megabrand Dupixent
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Sanofi s mRNA strategy adds biggest piece yet with $3 2B Translate Bio buyout

Sanofi s mRNA strategy adds biggest piece yet with $3 2B Translate Bio buyout
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.

Bristol-Myers, Sanofi Must Pay $834 Million Over Plavix

Bristol-Myers, Sanofi Must Pay $834 Million Over Plavix Bloomberg 2/16/2021 Jef Feeley © BLOOMBERG NEWS Seventy-five milligram tablets of Bristol-Myers Squibb blood thinner Plavix is arranged for an illustration at Skenderian Apothecary in Cambridge, Massachusetts on Thursday, Jan. 25, 2007. (Bloomberg) Bristol-Myers Squibb Co. and Sanofi were ordered to pay the state of Hawaii more than $834 million for illegally marketing their blockbuster blood-thinning drug Plavix in a manner that put some users’ lives at risk. Popular Searches Judge Dean Ochiai in Honolulu concluded Monday the drugmakers misleadingly marketed Plavix and failed to properly warn consumers in the state about its health risks. The companies produce the medicine as part of a joint venture.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.